ReviewToxins2026
Overview of Current Regulatory and Methodological Approaches for the Risk Assessment of Mycotoxins.
Review in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risk assessment is a dynamic and continuously evolving process aimed at characterizing the potential adverse effects on life and health arising from exposure to hazards. Among these hazards, mycotoxins represent one of the most significant and widely investigated contaminants in food and feed. This review aims to summarize current knowledge on mycotoxin risk assessment practice, both for single substances and for cumulative risk assessment, and to provide practical guidance for future researchers. As individual substances, mycotoxins are well characterized from a toxicological perspective, and numerous risk assessments have been conducted globally across a wide range of food products. Although well-established methodological frameworks exist to support the cumulative risk assessment of mycotoxins, further efforts are needed to define common assessment groups, especially considering the pleiotropic nature of these compounds.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.